Neuramis Lidocaine

Neuramis with Lidocaine: Integrated Anesthetic Across the Neuramis HA Filler Range

Neuramis with Lidocaine refers not to a single specific product, but to the **integration of 0.3% lidocaine hydrochloride** into several dermal fillers within the **Neuramis range** manufactured by **LG Chem Life Sciences**. This formulation feature is available across various viscosities and indications (e.g., Neuramis Deep Lidocaine, Neuramis Super Lidocaine, Neuramis Volume Lidocaine). Its primary purpose is to **significantly enhance patient comfort** during the injection procedure by providing **immediate local anesthesia** directly within the hyaluronic acid (HA) gel itself.https://skin-reboot.com/

**Core Technology & Properties:**
* **Premixed Monophasic NASHA Gel:** All Neuramis fillers feature a homogeneous, non-animal stabilized hyaluronic acid matrix, cross-linked with BDDE for longevity and tissue integration. The lidocaine is uniformly dispersed within this gel.
* **Integrated 0.3% Lidocaine HCl:** This concentration is standardized across lidocaine-containing Neuramis products. It works rapidly upon injection to block local pain signals.
* **Preserved Gel Properties:** The addition of lidocaine does not fundamentally alter the core rheological properties (G-prime, cohesivity, viscosity) or HA concentration of the specific Neuramis variant (e.g., Deep remains high-G prime for volumizing; Super/VoIume remain softer for superficial lines).
* **Consistent Performance:** The gel flows and integrates predictably like its non-lidocaine counterpart, while delivering anesthetic effect.

**Mechanism of Action (Lidocaine):**
1. **Local Nerve Block:** Lidocaine diffuses rapidly from the gel upon injection.
2. **Sodium Channel Blockade:** It binds to voltage-gated sodium channels on neuronal cell membranes.
3. **Pain Signal Inhibition:** By preventing sodium influx, lidocaine halts the initiation and conduction of pain impulses along the nerve fibers in the treated area.
4. **Rapid Onset:** Provides noticeable pain reduction within seconds to minutes of injection.

**Benefits & Purpose:**
* **Enhanced Patient Comfort:** Significantly reduces the pain and discomfort associated with needle insertion and product deposition.
* **Improved Patient Experience:** Leads to higher patient satisfaction and tolerance, especially for sensitive areas or multiple injections.
* **Simplified Procedure:** Eliminates or reduces the need for separate anesthetic injections or prolonged topical numbing application times, potentially streamlining the treatment process.
* **Reduced Anxiety:** Minimizing pain helps alleviate patient anxiety during the procedure.

**Key Considerations:**
* **Not a Standalone Product:** Always used as part of a specific Neuramis filler (e.g., “Neuramis Deep *with* Lidocaine”).
* **Adjunctive Anesthesia:** While effective, practitioners may still use topical anesthetics (e.g., LMX, EMLA) beforehand, especially for very sensitive patients or areas like lips, to maximize comfort during needle entry.
* **Safety & Contraindications:** Standard filler risks apply. **Critical:** Must screen patients for **lidocaine hypersensitivity or allergy** (rare but possible). Contraindicated in patients with known severe allergy to amide-type local anesthetics.
* **Aspiration:** Aspiration before injection remains crucial to avoid intravascular injection, regardless of lidocaine presence.
* **Onset & Duration:** Lidocaine effect is rapid but relatively short-lived, primarily covering the injection period itself. It does not prolong the filler’s aesthetic effect.
* **Regulatory:** CE marked (Europe/international) for specific lidocaine-containing variants. Not FDA-approved in the USA.

Integrating 0.3% lidocaine directly into Neuramis fillers represents a significant advancement in patient-centered care, making dermal filler treatments more comfortable and accessible while leveraging LG Chem’s established monophasic HA technology.CONTACT US